Amgen asks Fed Circ to rehear $1.1bn Juno patent suit

16-11-2021

Alex Baldwin

Amgen asks Fed Circ to rehear $1.1bn Juno patent suit

Sundry Photography / Shutterstock.com

Amgen and two research centres have thrown their support behind Bristol Myers Squibb subsidiary Juno Therapeutics to help restore a $1.1 billion patent judgment against Kite Pharma that was overturned by the US Court of Appeals for the Federal Circuit.


Amgen, Juno Therapeutics, Federal Circuit, patents

LSIPR